<DOC>
	<DOCNO>NCT00358722</DOCNO>
	<brief_summary>Fermagate phosphate binder absorbs phosphate food , reduce amount body absorb . The purpose study look safety fermagate long period time .</brief_summary>
	<brief_title>An Evaluation Long-term Safety Magnesium Iron Hydroxycarbonate</brief_title>
	<detailed_description>High level phosphate blood link serious effect , due calcium imbalance ( high level parathyroid hormone ( PTH ) , bone disease , formation calcium deposit body , blood-vessel disease ) . This study open-label , multi-centre , single-group , 24-week study fermagatebonate . Subjects participate study take least one dose double-blind study medication IH 001 study either complete study IH 001 withdrawn due reason adverse event ( AE ) consider related study treatment .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<criteria>1 . Taken least one dose doubleblind medication study IH 001 either complete study IH 001 withdrawn due reason AE consider related study treatment 2 . Male female subject active haemodialysis , age 18 year 3 . Willing abstain take phosphate binder oral magnesium , aluminium , ironcontaining product preparation , study medication ; 4 . Willing avoid intentional change diet fasting , diet overeat ; 5 . Willing maintain usual type dose Vitamin D supplementation . 1 . Participation clinical trial use investigational product device within previous 4 month ; 2 . A significant history alcohol , drug solvent abuse opinion investigator ; 3 . Any disease condition , physical psychological , opinion investigator would compromise safety subject increase likelihood subject withdrawn ; 4 . Clinically significant laboratory finding ( subject population ) opinion investigator . 5 . Any malignancy exception basal cell carcinoma ; 6 . A history motility disorder intestine , include , limited , gastroparesis , ileus , pseudoobstruction , megacolon , mechanical obstruction ; 7 . A significant illness 4 week screen ; 8 . Taking medication seizure ; 9 . A history haemochromatosis ; 10 . A history serum ferritin concentration â‰¥ 1000 ng/mL ( exclude transient , treatmentinduced ferritin elevation ) ; 11 . A history dysphagia swallow disorder ; 12 . Female subject lactate pregnant . Women childbearing potential ( premenopausal surgically sterilise ) unless abstain sexual intercourse use reliable contraceptive method , , barrier method , hormone intrauterine device ; 13 . Current haemoglobin concentration &lt; 10.00 g/dL ; 14 . Allergy IMP constituent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>